RSABE… [Regulatives / Guidelines]

posted by Loky do – Egypt, 2021-02-24 15:30 (457 d 14:09 ago) – Posting: # 22230
Views: 1,870

Hi Dear Helmut,

Many thanks for your reply :-D:-D

» Which book are you referring to?
»
» For the FDA you can apply RSABE for any PK metric (AUCs, partial AUCs, Cmax, :blahblah:) if its \(\small{s_{\textrm{wR}}\geq 0.294\;(CV_{\textrm{wR}}\geq\approx0.300469\ldots)}\)
» If \(\small{s_{\textrm{wR}}<0.294}\) you have to evaluate the respective PK metric for ABE.

I didn't find this statement in FDA guidance for bioequivalence studies just in progesterone guidance so, is it enough to refer to this guide while submitting the study to regulatory (as the intrasubject variability CV% equal 57%, partially replicate design), or is there another guide would support this way? please advice?

Thanks in advance

Complete thread:

UA Flag
Activity
 Admin contact
22,110 posts in 4,630 threads, 1,567 registered users;
online 11 (0 registered, 11 guests [including 2 identified bots]).
Forum time: Saturday 06:39 CEST (Europe/Vienna)

We can teach from our experience,
but we cannot teach experience.    Sasha Azevedo

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5